Hercules Capital, Inc. HTGC

Hercules Capital, Inc. es una empresa de finanzas especializada. Se enfoca en proporcionar préstamos garantizados senior a empresas respaldadas por capital de riesgo e instituciones en una variedad de industrias tecnológicas, de ciencias de la vida y de tecnologías sostenibles y renovables. La empresa es una compañía de inversión cerrada, gestionada internamente y no diversificada. Su objetivo de inversión es maximizar el rendimiento total de su cartera generando ingresos actuales de inversiones en deuda y apreciación de capital de inversiones relacionadas con warrants y acciones. Busca invertir en una variedad de empresas activas en subsectores de la industria tecnológica caracterizados por productos o servicios que requieren tecnologías avanzadas, incluyendo, entre otros, software y hardware de computadoras, sistemas de redes, semiconductores, equipos de capital de semiconductores, infraestructura de tecnología de la información, servicios de consumo y empresariales en Internet, telecomunicaciones, equipos de telecomunicaciones, energía renovable, medios de comunicación y ciencias de la vida.

Con 60 acciones de HTGC (USD 1.002,60) habrías recibido USD 112,80 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Hercules Capital (HTGC) Stock Sinks As Market Gains: Here's Why

  Hercules Capital (HTGC) closed at $16.74, down 1.18%, underperforming the S&P 500's 0.73% gain. The stock has declined 4.4% over the past month. The company is expected to report unchanged EPS of $0.49 with projected revenue growth of 2.98% year-over-year. For the full year, earnings are forecast to grow 2.09% to $1.95 per share. HTGC holds a Zacks Rank #3 (Hold) with a Forward P/E of 8.69, trading at a premium to its industry average of 7.49.

  

• Zacks Investment Research 23 sept

  Here's Why Hercules Capital (HTGC) Fell More Than Broader Market

  Hercules Capital (HTGC) closed down 1.45% and underperformed the S&P 500. The specialty finance company is expected to post steady EPS of $0.49 with revenue growth of 2.98% year-over-year. For fiscal year 2026, earnings are projected to grow 2.09% to $1.95 per share with revenue increasing 8.56% to $578.1 million. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 8.83, trading at a premium to its industry average of 7.98.

  

• Zacks Investment Research 9 sept

  Is Hercules Capital (HTGC) a Buy as Wall Street Analysts Look Optimistic?

  While Wall Street analysts maintain an optimistic view of Hercules Capital with an average brokerage recommendation of 1.50 (Strong Buy/Buy), the article cautions that brokerage recommendations often have a positive bias and may not reliably predict stock performance. The Zacks Rank system rates HTGC as a #3 (Hold), citing unchanged earnings estimates of $1.95 for the current year, suggesting the stock may perform in line with the broader market in the near term.

  

• GlobeNewswire Inc. 29 jun

  4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

  4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.